The Salt Study for Heart Failure

April 27, 2026 updated by: Maya Guglin, MD

Evaluating Effect of Low-Sodium and Regular Diets on Heart Failure Outcomes

The purpose of this study is to understand if low sodium (cardiac) diet is indeed necessary for better health outcomes in patients who suffered heart failure. This study will investigate the association between sodium intake and risk for 30-day re-admission in Heart Failure (HF) patients.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

500

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Above 18 years of age
  • Hospitalization due to Heart Failure admitted within 24 hours

Exclusion Criteria:

  • Concomitant hypertension (blood pressure >150/90 mmHg on admission)
  • End stage renal disease (on hemodialysis or peritoneal dialysis
  • Cardiogenic shock

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Normal Salt Diet
3-4 gm/day salt diet
Other: Normal Salt Diet
This study will allow regular diet 3-4 g Na-Salt per day in patients with acute HF as an intervention, because the standard recommendation for such patients is cardiac diet with 2 g Na per day. The intervention will end when the patient is discharged from the hospital. They will follow routine clinical care recommendations after discharge from hospital.
Placebo Comparator: Cardiac Diet
2 gm/day salt diet
Other: Cardiac Diet
This arm of study will allow the cardiac diet with 2 g Na per day, that is standard recommendation for HF patients. They will follow routine clinical care recommendations after discharge from hospital.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length of hospital stay
Time Frame: Hospital admission to time of discharge assessed up to 1 year
number of days the patient remains hospitalized
Hospital admission to time of discharge assessed up to 1 year
30-day readmission
Time Frame: 30 days after discharge from hospital after index event
readmission to hospital within 30 days of discharge from the index event
30 days after discharge from hospital after index event
NT-proBNP on discharge
Time Frame: time of hospital admission to 30 days after discharge
Measurement of blood levels of NT-ProBNP a biomarker for diagnosing and assessing the severity of heart failure.
time of hospital admission to 30 days after discharge
Loop diuretic requirement during index admission
Time Frame: time of hospital admission to 30 days after discharge
Furosemide, torsemide, and bumetanide are specific loop diuretics used in the treatment of fluid overload / retention conditions like congestive heart failure.
time of hospital admission to 30 days after discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Maya Guglin, MD

Investigators

  • Principal Investigator: Maya Guglin, MD, Rutgers University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 21, 2026

Primary Completion (Estimated)

November 10, 2027

Study Completion (Estimated)

November 1, 2028

Study Registration Dates

First Submitted

March 11, 2026

First Submitted That Met QC Criteria

April 27, 2026

First Posted (Actual)

May 1, 2026

Study Record Updates

Last Update Posted (Actual)

May 1, 2026

Last Update Submitted That Met QC Criteria

April 27, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Pro2025001253

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on Normal Salt Diet

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe